Share ownership Summit Therapeutics Inc.

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:15:06 16/03/2026 GMT			5-day change	1st Jan Change
15.90 ^USD	-1.36%		+1.27%	-8.98%

03-11	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03-02	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM

Share class: Summit Therapeutics Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	737,448,146	115,304,655 ( 15.64 %)	0	15.64 %

Major shareholders: Summit Therapeutics Inc.

Name	Equities	%	Valuation
Robert Duggan 74.84 %	580,304,655	74.84 %	9 627 M $
Baker Bros. Advisors LP 4.693 %	36,391,063	4.693 %	604 M $
Michelle Xia 4.134 %	32,057,147	4.134 %	532 M $
Mahkam Zanganeh 3.328 %	25,801,154	3.328 %	428 M $
Fidelity Management & Research Co. LLC 1.723 %	13,360,807	1.723 %	222 M $
Vanguard Fiduciary Trust Co. 1.442 %	11,177,220	1.442 %	185 M $
T. Rowe Price International Ltd. 1.209 %	9,371,415	1.209 %	155 M $
BlackRock Advisors LLC 1.028 %	7,972,891	1.028 %	132 M $
STATE STREET CORPORATION 0.8559 %	6,636,361	0.8559 %	110 M $
Geode Capital Management LLC 0.4059 %	3,147,480	0.4059 %	52 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	82.72%
Institutional	13.14%
Other	1.19%
State Street Corp.	0.86%
Manulife Financial Corp.	0.06%
Skandinaviska Enskilda Banken AB	0.04%
SEI Investments Co.	0.01%
Governments	0.01%
Unknown	1.97%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	82.73%
United States	12.46%
United Kingdom	1.45%
Hong Kong	0.37%
Canada	0.23%
Switzerland	0.19%
Norway	0.19%
Ireland	0.17%
Luxembourg	0.09%
Sweden	0.05%
Australia	0.04%
China	0.02%
France	0.02%
Puerto Rico	0.01%
Spain	0.01%

Based on 1000 largest holdings

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Employees

265

Sector

Biotechnology & Medical Research

More about the company